Insulin Aspart
Insulin aspart (B28-Asp human insulin analog)
51 Amino Acids · MW: 5825.8 Da
Amino Acids
51
Molecular Weight
5825.8 Da
Half-life
About 1-3 hours
Research Score
4.9
Studies
11000
Storage
Store lyophilized at -20°C, reconstituted at 2-8°C
What is Insulin Aspart?
A rapid-acting insulin analog with an amino-acid substitution at B28 that promotes faster absorption after injection. It is widely used to blunt postprandial glucose excursions in diabetes research and clinical practice.
Key Benefits & Mechanisms
Fast post-meal glucose lowering
Predictable onset
Flexible mealtime administration
Compatible with pump therapy
Research Summary
Research consistently shows faster onset and earlier peak action than regular human insulin. It is commonly studied for meal-time glycemic control and pump-based insulin delivery.
Related Peptides
Insulin Lispro
Insulin lispro (B28-Lys, B29-Pro human insulin analog)
A rapid-acting insulin analog with a reversed B28/B29 sequence that speeds absorption after subcutaneous injection. It is used to reduce postprandial hyperglycemia and to support flexible mealtime insulin strategies.
Diabetes & MetabolicInsulin Glargine
Insulin glargine (A21Gly,B31Arg,B32Arg human insulin analog)
A long-acting basal insulin analog engineered for slow release from the subcutaneous depot. It provides relatively flat day-long insulin coverage and is used to control fasting glucose.
Diabetes & MetabolicInsulin Degludec
Insulin degludec (desB30, acylated ultra-long-acting insulin analog)
An ultra-long-acting insulin analog designed with a fatty-acid side chain to form a slow-release depot. It is valued for very flat pharmacokinetics and flexible once-daily basal dosing.
Diabetes & MetabolicExendin-4
Exendin-4 (synthetic exenatide)
A 39-amino-acid GLP-1 receptor agonist originally isolated from Heloderma saliva. It enhances glucose-dependent insulin secretion and shows strong beta-cell anti-apoptotic activity in preclinical diabetes models.
Diabetes & Metabolic